Survodutide is dual glucagon receptor and GLP-1 receptor agonist peptide, developed as BI 456906 (formula C192H289N47O61, average mass 4,232 g/mol, CAS 2805997-46-8). Survodutide is sold here for laboratory research in 1 size (10mg), from $160.00 a vial. It is not an FDA-approved medicine. Research use only, and never for people or animals.
Survodutide specifications
| Product name | Survodutide |
|---|---|
| Formula | C192H289N47O61 |
| Average mass | 4,232 g/mol |
| CAS number | 2805997-46-8 |
| Physical form | Freeze-dried powder, a solid cake in a sealed vial |
| Appearance | White to off-white cake |
| Sizes on this page | 10mg |
| Purity specification | ≥99% by RP-HPLC. The number for the lot you receive is whatever its own certificate says. |
| Identity check | Mass spectrometry, read against the mass this compound should have |
| Net content | Weighed per lot and reported separately from purity |
| Lot documentation | Tested by Kovera Labs; each lot's certificate posts here when it is reported |
| Storage | Sealed, cold and out of the light |
| Ships from | Santa Ana, California by USPS with tracking on every order, same business day on verified in-stock orders placed before 12 PM Pacific |
| Intended use | Laboratory research only. Not for human or animal use. |
What is Survodutide, and what is it used for?
Supplier lists write it as peptide Survodutide; every one of those is this record, and the lot certificate further down counts for more than the wording on a label.
Chemically: molecular formula C192H289N47O61, average mass 4232 g/mol (PubChem CID 171378821). Those figures are what the identity test on a certificate is read against.
Dual glucagon receptor and GLP-1 receptor agonist peptide, developed as BI 456906.
Agonist at both the glucagon receptor (GCGR) and the GLP-1 receptor. The two-arm design follows the same logic as retatrutide's glucagon arm: GLP-1 receptor agonism acts on calorie intake, glucagon receptor agonism acts on energy expenditure and hepatic metabolism.
Investigational, developed by Boehringer Ingelheim. Studied in phase II randomised placebo-controlled trials in type 2 diabetes and in metabolic liver disease.
No approved product. Adverse events, predominantly gastrointestinal, were reported at a substantially higher rate than for the comparator in the published phase II trial.
Survodutide for sale: 10mg vials, price per mg
Survodutide is sold in 1 size here, 10mg, from $160.00 a vial. Every way of buying is in the table; the per-mg figure under each price is the one that compares across sizes.
Volume and subscription pricing by size
| Size | One vial | 10–19 vials−10% | 20 vials−15% | Subscribe monthly−6% from shipment 2 | Availability |
|---|---|---|---|---|---|
| Survodutide 10mg | $160.00$16.00/mg | $144.00a vial · $14.40/mg | $136.00a vial · $13.60/mg | $150.40a vial, shipment 2 on · $15.04/mg | Backordered — waitlist |
Volume tiers are per size and do not combine across sizes (see bulk pricing). Subscribe & Save takes 6% every month, 4% every 2 months or 2% every 3 months off from shipment 2, two shipments minimum, and stacks on the volume tier: the lowest this record ever bills is $12.78 per mg, twenty 10mg vials on a monthly subscription from shipment 2 onward.
Nothing is added at checkout except the USPS shipping you choose; dispatch and delivery are the same on every order. The cost-per-milligram tool ranks the whole catalog by price per mg.
Where to buy Survodutide: what to check before you order from anyone
Survodutide for sale, or Survodutide peptide for sale, means this page: one record, 1 size. You can buy Survodutide online here with guest checkout; verified in-stock orders placed before 12 PM Pacific are dispatched the same day.
Before ordering Survodutide from anyone, us included, run the 5 checks on verifying a certificate; the first is that the report resolves on the laboratory's own site, and a seller who cannot pass them is asking for the trust a certificate exists to replace.
Survodutide vs Tirzepatide and Semaglutide: different molecules, separate records
Survodutide vs Tirzepatide, or Tirzepatide vs Survodutide, is the comparison people search most, with Semaglutide close behind, and they are not the same thing. Each is a different molecule with a different formula, mass and research record, and each has its own certificate here.
Tirzepatide vs Survodutide: the same comparison, side by side
| Record | Class | Formula | Avg. mass | Sizes here |
|---|---|---|---|---|
| Survodutide | Dual glucagon receptor and GLP-1 receptor agonist peptide, developed as BI 456906. | C192H289N47O61 | 4232 | 10mg from $160.00 |
| Tirzepatide | A peptide that works on the GIP and GLP-1 receptors at the same time. | C225H348N48O68 | 4813 | 5mg · 10mg · 15mg · 20mg · 30mg · 40mg · 50mg · 60mg · 70mg · 80mg · 90mg · 100mg · 110mg · 120mg from $50.00 |
| Semaglutide | A peptide that works on the GLP-1 receptor. | C187H291N45O59 | 4114 | 5mg · 10mg · 15mg · 20mg · 30mg from $55.00 |
Documentation compared in full: Survodutide vs Tirzepatide, side by side · Survodutide vs Semaglutide, side by side.
Survodutide guides and documentation
Written to answer the questions that come up around Survodutide specifically, what its paperwork should show, how it is handled, and how to judge a supplier selling it.
- Survodutide certificates of analysis, field by field, and how to check one at the lab
- Survodutide identity testing: what the mass spectrum fixes, and what it leaves open
- Survodutide storage and stability: what shortens the shelf life, and what protects it
The full library, grouped by what you came to answer, is in the laboratory guides.
The Survodutide certificate: lot, purity, identity, and how to verify it
A certificate answers identity, purity and net content as three separate questions, each with the method that produced it and the date it was run, how to read one covers what each field does and does not cover. For Survodutide that means a mass spectrum landing on 4,232 g/mol for C192H289N47O61, the figure published against PubChem CID 171378821.
Survodutide certificates post here and in the certificate index when Kovera Labs reports on the lot.
Solution arithmetic for the bench, with no administration guidance: the vial concentration calculator, preset to Survodutide.
Where the FDA stands on Survodutide
FDA status, and what this listing is Not an FDA-approved drug product
The FDA has not approved this compound for anything, and nothing in this catalog is a medicine.
Status verified 2026-08-25. Check the primary source before relying on this summary.
It is sold as laboratory material under the research-use restriction below. Being listed is not an approval, and not a claim that it is safe, effective or right for any purpose.
Survodutide research: what the published studies examine
Status: No FDA-approved application. This compound is sold as laboratory material. Where research on it has been published, it sits at the animal, cell or early-human stage, and this record does not summarize what it found. A supplier is not a neutral judge of evidence about its own catalog.
Survodutide is a dual agonist at the glucagon receptor and the GLP-1 receptor. It is worth positioning it against the other multi-receptor incretins on this catalog, because the receptor sets differ in ways that matter: tirzepatide pairs GLP-1 with GIP, survodutide pairs GLP-1 with glucagon, and retatrutide combines all three. The glucagon arm is the one survodutide shares with retatrutide and the one that distinguishes both from tirzepatide, and it is proposed to act on energy expenditure and hepatic fat handling rather than on calorie intake.
Glucagon receptor agonism is also the least established of the three arms across this whole class, and adding it is a genuine pharmacological bet rather than an obvious improvement.
| Reported observation | Model | Source |
|---|---|---|
| In a phase II randomised, double-blind, placebo-controlled parallel-group trial of 413 participants with type 2 diabetes on background metformin, with an open-label semaglutide comparator arm, adverse events were reported for 77.8% of survodutide-treated participants — mainly gastrointestinal — against 52.5% receiving placebo and 52.0% receiving semaglutide. The authors state that dose-related gastrointestinal adverse events could be mitigated with slower dose escalation. | phase II randomised double-blind placebo-controlled trial, 413 adults with type 2 diabetes, active comparator | Bluher and colleagues, Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial, Diabetologia (2023)Sponsor-funded (Boehringer Ingelheim) with academic investigators. Cited here for the tolerability data; the efficacy endpoints are deliberately not reproduced. |
Open questions. The tolerability figure above is the most decision-relevant published fact about this compound and it is the one supplier copy omits: adverse events in roughly three-quarters of treated participants against about half on placebo and about half on the active comparator, predominantly gastrointestinal and dose-related. The compound is investigational with no approval anywhere, and the glucagon receptor arm — the feature that distinguishes it — is the least characterized part of the multi-receptor incretin story generally.
Glucagon receptor agonism raises hepatic glucose output as a matter of basic physiology, which is why these molecules pair it with GLP-1 rather than using it alone, and the net effect depends on that balance holding. This page does not reproduce clinical efficacy endpoints.
That is a deliberate and consistent choice across every incretin compound on this catalog: those results describe a supervised therapy given to patients under medical care, which is a different thing from laboratory material, and printing them beside a purchase control would blur that distinction rather than inform anyone. Tolerability findings from the same trials are reported, because how often a compound causes adverse events is a property of the compound.
Finally, the point that applies to every reseller including this one: a vial bearing one of these names is related to the developed molecule by claimed sequence identity alone, and that claim is exactly what an identity assay on the specific lot exists to test.
Each row above describes an observation in the stated model. None of it describes what Survodutide would do in a person or an animal outside that model, and none of it is a recommendation to use it for anything.
How to store Survodutide: refrigeration and shelf life
Keep the sealed vial cold and out of the light and it stays as it left the lab. Once it is mixed into a solution, how long it holds up depends on the compound, what it was mixed with, how strong the solution is and how cold it is kept — too many variables for anyone to print one shelf life on a label. So laboratories write the date on whatever they prepare and keep their own record of it.
For solution preparation arithmetic on the bench, concentration, per-graduation values and molarity, use the vial concentration calculator, which opens with the Survodutide sizes stocked here already loaded. It covers laboratory measurement only and contains no administration guidance.
